AGÕæÈ˹ٷ½

STOCK TITAN

Align Technology Announces Second Quarter 2025 Financial Results

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
  • Q2'25 total revenues were $1,012.4 million, up 3.4% sequentially and down 1.6% year-over-year
  • Q2'25 total revenues were favorably impacted by foreign exchange by approximately $26.4 million, or 2.7% sequentially, and favorably impacted by approximately $5.6 million, or 0.6% year-over-year(1)
  • Q2'25 Clear Aligner revenues were $804.6 million, up 1.0% sequentially and down 3.3% year-over-year
  • Q2'25 Clear Aligner volume was 644.4 thousand cases, up 0.3% sequentially and year-over-year
  • Q2'25 Imaging Systems and CAD/CAM Services revenues were $207.8 million, up 13.9% sequentially and up 5.6% year-over-year
  • Q2'25 operating income of $163.0 million and operating margin of 16.1%, non-GAAP operating margin of 21.3%(1)
  • Q2'25 GAAP operating margin was favorably impacted by foreign exchange by approximately 1.2 points sequentially and favorably impacted by approximately 0.2 points year-over-year(1)
  • Q2'25 diluted net income per share was $1.72, non-GAAP diluted net income per share was $2.49(1)
  • Q2'25 cash and cash equivalents were $901.2 million compared to $873.0 million as of Q1'25

TEMPE, Ariz.--(BUSINESS WIRE)-- Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero� intraoral scanners, and exocad� CAD/CAM software for digital orthodontics and restorative dentistry, today reported financial results for the second quarter ("Q2'25"). Q2'25 total revenues were $1,012.4 million, up 3.4% sequentially and down 1.6% year-over-year. Q2'25 total revenues were favorably impacted by foreign exchange of approximately $26.4 million, or 2.7% sequentially, and favorably impacted by approximately $5.6 million, or 0.6% year-over-year.(1) Q2'25 Clear Aligner revenues were $804.6 million, up 1.0% sequentially and down 3.3% year-over-year. Q2'25 Clear Aligner revenues were favorably impacted by foreign exchange of approximately $21.6 million, or 2.8% sequentially, and favorably impacted by approximately $4.5 million, or 0.6% year-over-year. Q2'25 Clear Aligner volume was up 0.3% sequentially and year-over-year. Q2'25 Imaging Systems and CAD/CAM Services revenues were $207.8 million, up 13.9% sequentially, and up 5.6% year-over-year. Q2'25 Imaging Systems and CAD/CAM Services revenues were favorably impacted by foreign exchange of approximately $4.8 million, or 2.3% sequentially and favorably impacted by approximately $1.0 million, or 0.5% year-over-year.(1)

Q2'25 operating income was $163.0 million, resulting in an operating margin of 16.1%. Foreign exchange favorably impacted Q2'25 operating margin by approximately 1.2 points sequentially and by approximately 0.2 points year-over-year.(1) On a non-GAAP basis, Q2'25 operating income was $215.9 million, resulting in an operating margin of 21.3%, up 2.3 points sequentially and down 1.0 points year-over-year. Q2'25 net income was $124.6 million, or $1.72 per diluted share. On a non-GAAP basis, Q2'25 net income was $181.1 million, or $2.49 per diluted share.

Commenting on Align's Q2'25 results, Align Technology President and CEO Joe Hogan said, “Our second quarter results were mixed. Total Q2 revenues of $1,012.4 million reflect solid year-over-year revenue growth for Systems and Services, driven primarily by stronger than expected sales of iTero Lumina� scanner wand upgrades-offset by lower-than-expected sales of full iTero Lumina Systems, and a slight year-over-year decrease in Clear Aligner revenues driven primarily by lower-than-expected volumes in Europe and North America. As a result, Q2 worldwide revenues and operating margins were below our Q2 outlook. During Q2, we continued to see strong consumer interest in Invisalign® treatment, as reflected by iTero scans and Invisalign doctor case submissions. However, we experienced uneven patient case conversion, which led to a lower than typical seasonal uptick in case starts which historically occurs late in the quarter. As we assessed our Q2 results and the activity in our customers� offices, we believe it was impacted in part by U.S. tariff turmoil in and outside of the U.S. and less affordable financing options for orthodontic treatment, as well as for capital equipment purchases. Recent dental industry surveys for the second quarter suggest there was less overall patient traffic, fewer orthodontic case starts, and patient hesitation toward elective procedures. 2025 marks the fourth consecutive year orthodontic starts are down, and third-party research reports indicate that practices that use both wires and brackets and clear aligners may have shifted more of their case starts to metal braces in Q2. Uncertainty not only impacts consumer purchasing decisions � but also the decisions that doctors make, especially practices who still use wires & brackets and weigh the sunk cost of their inventory and their available time over investing in digital solutions during times of financial uncertainty.�

Continued Hogan, “As we begin the third quarter and plan for the remainder of the year, our outlook anticipates the potential continued economic uncertainty and spending hesitancy that impacted demand for our clear aligners and new iTero scanner systems in the second quarter, even though we know consumer interest in Invisalign treatment remains strong*. We are evaluating actions to reduce costs and thoughtfully manage our investments while we continue to drive engagement and effectiveness of commercial and marketing programs that leverage our innovation and new product cycle across our clear aligners and scanners, especially those for teens and kids.�

*Data source: Google Trends

Financial Summary - Second Quarter Fiscal 2025

Ìý

Q2'25

Ìý

Q1'25

Ìý

Q2'24

Ìý

Q/Q Change

Ìý

Y/Y Change

Clear Aligner Shipments*

644,370

Ìý

642,305

Ìý

642,725

Ìý

+0.3%

Ìý

+0.3%

GAAP

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Net Revenues

$1,012.4M

Ìý

$979.3M

Ìý

$1,028.5M

Ìý

+3.4%

Ìý

(1.6)%

Clear Aligner

$804.6M

Ìý

$796.8M

Ìý

$831.7M

Ìý

+1.0%

Ìý

(3.3)%

Imaging Systems and CAD/CAM Services

$207.8M

Ìý

$182.4M

Ìý

$196.8M

Ìý

+13.9%

Ìý

+5.6%

Net Income

$124.6M

Ìý

$93.2M

Ìý

$96.6M

Ìý

+33.7%

Ìý

+29.0%

Diluted EPS

$1.72

Ìý

$1.27

Ìý

$1.28

Ìý

+$0.45

Ìý

+$0.43

Non-GAAP

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Net Income

$181.1M

Ìý

$156.9M

Ìý

$181.0M

Ìý

+15.5%

Ìý

+0.1%

Diluted EPS

$2.49

Ìý

$2.13

Ìý

$2.41

Ìý

+$0.36

Ìý

+$0.09

Ìý

Changes and percentages are based on actual values. Certain tables may not sum or recalculate due to rounding.
*Clear Aligner shipments include Doctor Subscription Program Touch-Up cases.

As of June 30, 2025, we had approximately $901.2 million in cash and cash equivalents, compared to over $873.0 million as of March 31, 2025. As of June 30, 2025, we had $300.0 million available under our revolving line of credit.

Align is also announcing today that we expect to take a series of actions in the second half of fiscal 2025 to streamline operations and reallocate resources to better align with our long-term growth and profitability objectives. These actions are intended to sharpen operational focus, reduce ongoing costs, and enhance capital efficiency. First, we expect to realign certain business groups and reduce our global workforce. Second, we are looking to optimize our manufacturing footprint and dispose of certain manufacturing capital assets as we transition to next-generation manufacturing technologies, increase automation, and regionalize manufacturing to be closer to our customers. We expect these actions will incur one-time charges of approximately $150 million to $170 million in the second half of 2025, primarily for the write-down of assets, accelerated depreciation expense, and restructuring charges. We expect approximately $40 million of these charges to be in cash, with the remainder in non-cash charges. We expect approximately $50 million to $60 million of these charges in Q3�25. We expect these actions to deliver cost savings that will allow us to achieve a GAAP operating margin of approximately 13.0%�14.0% and a non-GAAP operating margin slightly above 22.5% in FY 2025. For FY 2026, we expect these actions to improve our GAAP and non-GAAP operating margins by at least 100 basis points year-over-year.

“We are evaluating these difficult but, we believe, necessary actions to position us for sustainable, long-term success and improved profitability,� said John Morici, Align CFO and executive vice president, global finance. “While these decisions may impact valued members of our team, we believe they are essential to ensure we are positioned for upcoming technology changes and to remain agile and focused in a rapidly evolving market. We are committed to executing our strategy with discipline and purpose.�

Align Announcement Highlights

  • On July 22, 2025, Align announced commercial availability in Malaysia of the Invisalign® System with mandibular advancement featuring occlusal blocks designed specifically to address Class II skeletal and dental correction by simultaneously advancing the mandible while aligning the teeth.
  • On July 22, 2025, Align announced that the Invisalign® Palatal Expander System has been notified as Class B medical device by Malaysia Medical Device Authority and is now commercially available in Malaysia for broad patient applicability, including growing children, teens and adults (with surgery or other techniques).
  • On July 16, 2025, Align announced a collaboration with Disney’s highly anticipated movie sequel "Freakier Friday," which opens in theaters on August 8, 2025. The collaboration will bring Align’s commitment to building teen confidence through Invisalign® brand product placements, highlighting how the Invisalign clear aligner system offers an effective,* convenient, and modern way to achieve a confident smile. *Data on file, Align Technology.
  • On July 14, 2025, Align announced that the Invisalign® Palatal Expander System was approved as a Class B medical device by the Central Drugs Standard Control Organization and is commercially available in India for broad patient applicability, including growing children, teens and adults (with surgery or other techniques).
  • On July 14, 2025, Align announced commercial availability in India of the Invisalign® System with mandibular advancement featuring occlusal blocks designed specifically to address Class II skeletal and dental correction by simultaneously advancing the mandible while aligning the teeth.
  • On July 2, 2025, Align announced that its Board of Directors appointed Britt Vitalone, Executive Vice President and Chief Financial Officer, McKesson Corporation, to Align’s Board of Directors and its Audit Committee.
  • On June 27, 2025, Align shared highlights from the 2025 Invisalign® Asia Pacific Summit, connecting with over 2,000 doctors and practice staff.
  • On June 17, 2025, Align launched an integrated consumer and professional brand campaign focused on Invisalign treatment for kids and teens.
  • On June 2, 2025, Align announced the award of twelve research grants to universities under the company’s fifteenth Annual Research Award Program, with $300,000 in research grants awarded.
  • On May 22, 2025, Align announced a new professional marketing initiative spanning across the EMEA region and North America to provide doctors with a platform to share their stories about transforming smiles and changing lives for their patients and practices.
  • On May 15, 2025, Align announced that the Invisalign® Palatal Expander System was approved by the National Medical Products Administration in China.
  • On April 24, 2025, Align announced the commercial availability in the U.S. and Canada of the Invisalign® System with mandibular advancement featuring occlusal blocks designed specifically to address Class II skeletal and dental correction by simultaneously advancing the mandible while aligning the teeth.
  • On April 1, 2025, Align announced that the Invisalign® System with mandibular advancement featuring occlusal blocks was made commercially available to Invisalign-trained doctors in Australia and New Zealand.

Q2'25 Stock Repurchase

  • During Q2'25, we repurchased approximately 585.1 thousand shares of our common stock at an average price of $164.14 per share, completing the $225.0 million open market repurchase initiated in Q1'25. This completed our $1.0 billion stock repurchase program approved in January 2023, in its entirety.
  • In April 2025, our Board of Directors authorized a plan to repurchase up to $1.0 billion of our common stock (“April 2025 Repurchase Programâ€�), none of which has been utilized. The April 2025 Repurchase Program is expected to be completed over a period of up to three years.

UK VAT Update as of July 30, 2025:

  • As previously disclosed in our Q1â€�25 earnings release and conference call, on April 24, 2025, we received a favorable ruling in which the UK tribunal determined that our clear aligners are exempt from VAT.
  • In June of 2025, HMRC filed a Petition to Appeal to the Upper Tribunal to attempt to challenge the First-tier Tribunal's decision. On July 15, HMRC was given permission to appeal and has until August 15, 2025 to do so.
  • For impacted customers, effective August 1, 2025, Align invoices will no longer include the United Kingdom VAT rate of 20% for all Invisalign treatment packages that are ClinCheck® approved on or after August 1, 2025, and for refinement and replacement aligners, Viveraâ„� retainers, PVS processing fees, and additional aligners orders placed on or after August 1, 2025. At the same time, we will simultaneously adjust prices for our clear aligners and retainers to keep the overall price consistent.

Tariff Update as of July 30, 2025:

  • There is no material change to the expected impact of U.S. tariffs and we refer you to our Q1â€�25 press release and earnings materials, as well as our Q2â€�25 webcast slides which include specifics regarding potential impacts of U.S. tariffs.

Fiscal 2025 Business Outlook

Assuming no circumstances occur beyond our control, such as foreign exchange, macroeconomic conditions, and changes to currently applicable tariffs that could impact our business:

Q3'25:

  • We expect Q3â€�25 worldwide revenues to be in the range of $965 million to $985 million, down sequentially from Q2â€�25.
  • We expect Q3â€�25 Clear Aligner volume to be down sequentially as a result of Q3 seasonality and Q3â€�25 Clear Aligner average selling price (“ASPâ€�) to be slightly up sequentially, due to favorable foreign exchange at current spot rates, partially offset by a continued product mix shift to non-comprehensive clear aligner products with lower list prices.
  • We expect Q3â€�25 Systems and Services revenues to be down sequentially because of Q3 seasonality.
  • We expect Q3â€�25 worldwide GAAP gross margin to be 64% to 65%, down sequentially by approximately 5 to 6 points, due to the incurrence of one-time charges expected to be approximately $45 to $55 million primarily for the write-down of assets, accelerated depreciation expense, and restructuring charges in Q3â€�25 and lower Clear Aligner volume. We expect non-GAAP gross margin to be flat from Q2â€�25.
  • We expect Q3â€�25 GAAP operating margin to be 10.5% to 11.5%, down sequentially by approximately 5 to 6 points, due to the incurrence of one-time charges expected to be approximately $50 to $60 million primarily for the write-down of assets, accelerated depreciation expense, and restructuring charges in Q3â€�25 and lower Clear Aligner volume. We expect the majority of these charges to be non-cash charges, with approximately $5 million in cash charges. We expect Q3â€�25 Non-GAAP operating margin to be approximately 22%.

For fiscal 2025:

  • We expect 2025 Clear Aligner volume growth to be low-single digits and revenue growth to be flat to slightly up from 2024, assuming foreign exchange at current spot rates.
  • We expect 2025 Clear Aligner ASPs to be down year-over-year due to a continued product mix shift to non-comprehensive clear aligners with lower list prices, and continued growth in our emerging markets with products that may carry lower list prices, partially offset by favorable foreign exchange at current spot rates.
  • We expect 2025 Systems and Services year-over-year revenues to grow faster than Clear Aligner revenues.
  • We expect the 2025 GAAP gross margin to be 67% - 68%, down year-over-year by approximately 2 to 3 points, due to the incurrence of one-time charges expected to be approximately $115 to $130 million primarily for the write-down of assets, accelerated depreciation expense, and restructuring charges in the second half of 2025 and lower Clear Aligner volume. We expect the 2025 non-GAAP gross margin to be flat to slightly lower than the 2024 non-GAAP gross margin.
  • We expect the fiscal 2025 GAAP operating margin to be 13% - 14%, down year-over-year, by approximately 1 to 2 points below the 2024 GAAP operating margin due to the incurrence of one-time charges expected to be approximately $150 to $170 million. primarily for the write-down of assets, accelerated depreciation expense, and restructuring charges in the second half of 2025. Most of the one-time charges will be non-cash with the expected cash outlay for 2025 estimated at around $40 million. We expect the 2025 non-GAAP operating margin to be slightly above 22.5%.
  • We expect our investments in capital expenditures for fiscal 2025 to be between $100 million and $125 million. Capital expenditures primarily relate to technology upgrades as well as maintenance.

Align Webcast and Conference Call

We will host a conference call today, July 30, 2025, at 4:30 p.m. ET, 1:30 p.m. PT, to review our Q2'25 results, discuss future operating trends, and our business outlook. The conference call will also be webcast live via the Internet. To access the webcast, go to the "Events & Presentations" section under "Company Information" on Align's Investor Relations website at . To access the conference call, participants may register for the call at . An archived audio webcast will be available 2 hours after the call's conclusion and will remain available for one month.

About Non-GAAP Financial Measures

To supplement our condensed consolidated financial statements, which are prepared and presented in accordance with generally accepted accounting principles ("GAAP") in the United States ("U.S. GAAP"), we use the following non-GAAP financial measures: constant currency net revenues, constant currency gross profit, constant currency gross margin, constant currency income from operations, constant currency operating margin, non-GAAP gross profit, non-GAAP gross margin, non-GAAP total operating expenses, non-GAAP income from operations, non-GAAP operating margin, non-GAAP net income before provision for income taxes, non-GAAP provision for income taxes, non-GAAP effective tax rate, non-GAAP net income and non-GAAP diluted net income per share.

These non-GAAP financial measures exclude certain items that may not be indicative of our fundamental operating performance, including foreign currency exchange rate impacts, the effects of stock-based compensation, amortization of intangible assets related to certain acquisitions, restructuring and other charges, acquisition-related costs, associated tax impacts and discrete cash and non-cash charges or gains that are included in the most directly comparable GAAP financial measure.

Our management believes that the use of certain non-GAAP financial measures provides meaningful supplemental information regarding our recurring core operating performance. We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. We believe these non-GAAP financial measures are useful to investors because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making, and (2) they are used by our institutional investors and the analyst community to help them analyze the performance of our business.

There are material limitations to using non-GAAP financial measures as they are not prepared in accordance with U.S. GAAP and may be different from similarly titled non-GAAP financial measures used by other companies. Non-GAAP financial measures exclude certain items that may have a material impact upon our reported financial results, which can limit their usefulness for comparison purposes. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by management about which charges are excluded from the non-GAAP financial measures. We compensate for these limitations by analyzing current and future results on both a GAAP and non-GAAP basis and by providing specific information regarding the GAAP amounts excluded from these non-GAAP financial measures in our public disclosures. The presentation of non-GAAP financial information is meant to be considered in addition to, not as a substitute for, superior to, or in isolation from, the directly comparable financial measures prepared in accordance with U.S. GAAP. We urge investors to review the reconciliation of our GAAP financial measures to the comparable non-GAAP financial measures included herein and not to rely on any single financial measure to evaluate our business. For more information on these non-GAAP financial measures and a reconciliation of GAAP to non-GAAP measures, please see the tables captioned "Unaudited GAAP to Non-GAAP Reconciliation."

About Align Technology, Inc.

Align Technology designs and manufactures the Invisalign® System, the most advanced clear aligner system in the world, iTero� intraoral scanners and services, and exocad� CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 286.4 thousand doctor customers and are key to accessing Align’s 600 million consumer market opportunity worldwide. Over the past 28 years, Align has helped doctors treat approximately 20.8 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align� Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit for more information.

For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit . For additional information about the iTero digital scanning system, please visit . For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit .

Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.

Forward-Looking Statements

This news release, including the tables below, contains forward-looking statements, including statements of beliefs and expectations regarding our ability to successfully manage our business and operations, reduce costs, manage investments and pursue our strategic growth drivers, our expectations regarding the potential continued economic uncertainty and spending hesitancy of consumers, our expectations regarding our stock repurchase programs, our expectations for market opportunities, our expectations regarding a series of actions in the second half of fiscal 2025 to streamline operations and reallocate resources to better align our long-term growth with our profitability objectives and the expected timing and financial impact of any such actions, our expectations regarding the applicability of VAT to our Clear Aligner sales in the UK, our expectations for implemented or proposed tariffs, and our expectations for Q3�25 and fiscal year 2025 worldwide revenues, Clear Aligner volume, Clear Aligner ASPs, Systems and Services revenues, GAAP and non-GAAP operating margin, GAAP and non-GAAP gross margin, and 2025 capital expenditures. Forward-looking statements contained in this press release relating to expectations about future events or results are based upon information available to Align as of the date hereof. Readers are cautioned that these forward-looking statements reflect our best judgments based on currently known facts and circumstances and are subject to risks, uncertainties, and assumptions that are difficult to predict. As a result, actual results may differ materially and adversely from those expressed in any forward-looking statement.

Factors that might cause such a difference include, but are not limited to:

  • macroeconomic conditions, including inflation, fluctuations in currency exchange rates, higher interest rates, market volatility, threats or actual imposition of tariffs, customs duties and fees by nations and retaliatory actions, threats of or actual economic slowdowns or recessions or escalating trade wars and geopolitical tensions;
  • customer and consumer purchasing behavior and changes in consumer spending habits as a result of, among other things, prevailing macroeconomic conditions, levels of employment, health insurance coverage, wages, debt obligations, discretionary income, inflationary pressure, and declining consumer confidence;
  • implemented or proposed tariffs and retaliatory actions or other trade restrictions or measures taken by the United States and other countries that have or could impact our products and product sales;
  • variations in our geographic, channel and product mix, product launches, product pilots and product adoption, and selling prices regionally and globally, including product mix shifts to lower priced products or to products with a higher percentage of deferred revenue;
  • competition from existing and new competitors;
  • declines in, or the slowing of the growth of, sales of our clear aligners and intraoral scanners domestically and/or internationally and the impact either would have on the adoption of Invisalign products;
  • the economic and geopolitical ramifications of the military conflicts in the Middle East and Ukraine, and tensions involving Taiwan and South China Sea and our operations and assets in Israel and Russia;
  • our ability to implement and realize the anticipated benefits currently expected from actions to streamline operations and reallocate resources to better align our long-term growth with our profitability objectives;
  • the possibility that the development and release of new products or enhancements to existing products do not proceed in accordance with the anticipated timeline or may themselves contain bugs, errors, or defects in software or hardware requiring remediation and that the market for the sale of these new or enhanced products may not develop as expected;
  • the timing and availability and cost of raw materials, components, products and other shipping and supply chain constraints and disruptions;
  • unexpected or rapid changes in the growth or decline of our domestic and/or international markets;
  • rapidly evolving and groundbreaking advances that fundamentally alter the dental industry or the way new and existing customers market and provide products and services to consumers;
  • our ability to protect our intellectual property rights;
  • continued compliance with regulatory requirements;
  • the willingness and ability of our customers to maintain and/or increase product utilization in sufficient numbers;
  • our ability to sustain or increase profitability or revenue growth in future periods (or minimize declines) while controlling expenses;
  • expansion of our business and products;
  • the impact of excess or constrained capacity at our manufacturing and treat operations facilities and pressure on our internal systems and personnel;
  • the compromise of our systems or networks, including any customer and/or patient data contained therein, for any reason;
  • the timing of case submissions from our doctor customers within a quarter as well as an increased manufacturing costs per case; and
  • the loss of key personnel, labor shortages, or work stoppages for us or our suppliers.

The foregoing and other risks are detailed from time to time in our periodic reports filed with the Securities and Exchange Commission (SEC), including, but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on February 28, 2025 and our latest Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, which was filed with the SEC on May 8, 2025. Align undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

ALIGN TECHNOLOGY, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)

Ìý

Ìý

Three Months Ended

June 30,

Ìý

Six Months Ended

June 30,

Ìý

Ìý

Ìý

2025

Ìý

Ìý

2024

Ìý

Ìý

Ìý

2025

Ìý

Ìý

2024

Ìý

Net revenues

Ìý

$

1,012,449

Ìý

$

1,028,490

Ìý

Ìý

$

1,991,711

Ìý

$

2,025,921

Ìý

Cost of net revenues

Ìý

Ìý

304,332

Ìý

Ìý

305,862

Ìý

Ìý

Ìý

603,486

Ìý

Ìý

605,477

Ìý

Gross profit

Ìý

Ìý

708,117

Ìý

Ìý

722,628

Ìý

Ìý

Ìý

1,388,225

Ìý

Ìý

1,420,444

Ìý

Operating expenses:

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Selling, general and administrative

Ìý

Ìý

448,686

Ìý

Ìý

452,262

Ìý

Ìý

Ìý

896,315

Ìý

Ìý

904,084

Ìý

Research and development

Ìý

Ìý

96,398

Ìý

Ìý

92,193

Ìý

Ìý

Ìý

193,599

Ìý

Ìý

184,052

Ìý

Legal settlement loss

Ìý

Ìý

�

Ìý

Ìý

31,127

Ìý

Ìý

Ìý

4,178

Ìý

Ìý

31,127

Ìý

Total operating expenses

Ìý

Ìý

545,084

Ìý

Ìý

575,582

Ìý

Ìý

Ìý

1,094,092

Ìý

Ìý

1,119,263

Ìý

Income from operations

Ìý

Ìý

163,033

Ìý

Ìý

147,046

Ìý

Ìý

Ìý

294,133

Ìý

Ìý

301,181

Ìý

Interest income and other income (expense), net:

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Interest income

Ìý

Ìý

2,859

Ìý

Ìý

3,301

Ìý

Ìý

Ìý

8,175

Ìý

Ìý

7,693

Ìý

Other income (expense), net

Ìý

Ìý

7,624

Ìý

Ìý

(6,481

)

Ìý

Ìý

11,650

Ìý

Ìý

(6,622

)

Total interest income and other income (expense), net

Ìý

Ìý

10,483

Ìý

Ìý

(3,180

)

Ìý

Ìý

19,825

Ìý

Ìý

1,071

Ìý

Net income before provision for income taxes

Ìý

Ìý

173,516

Ìý

Ìý

143,866

Ìý

Ìý

Ìý

313,958

Ìý

Ìý

302,252

Ìý

Provision for income taxes

Ìý

Ìý

48,908

Ìý

Ìý

47,302

Ìý

Ìý

Ìý

96,120

Ìý

Ìý

100,660

Ìý

Net income

Ìý

$

124,608

Ìý

$

96,564

Ìý

Ìý

$

217,838

Ìý

$

201,592

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Net income per share:

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Basic

Ìý

$

1.72

Ìý

$

1.28

Ìý

Ìý

$

2.98

Ìý

$

2.68

Ìý

Diluted

Ìý

$

1.72

Ìý

$

1.28

Ìý

Ìý

$

2.98

Ìý

$

2.68

Ìý

Shares used in computing net income per share:

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Basic

Ìý

Ìý

72,565

Ìý

Ìý

75,184

Ìý

Ìý

Ìý

73,061

Ìý

Ìý

75,180

Ìý

Diluted

Ìý

Ìý

72,593

Ìý

Ìý

75,223

Ìý

Ìý

Ìý

73,098

Ìý

Ìý

75,315

Ìý

ALIGN TECHNOLOGY, INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)

Ìý

Ìý

June 30,
2025

Ìý

December 31,
2024

ASSETS

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Current assets:

Ìý

Ìý

Ìý

Ìý

Cash and cash equivalents

Ìý

$

901,157

Ìý

$

1,043,887

Accounts receivable, net

Ìý

Ìý

1,116,210

Ìý

Ìý

995,685

Inventories

Ìý

Ìý

243,750

Ìý

Ìý

254,287

Prepaid expenses and other current assets

Ìý

Ìý

186,941

Ìý

Ìý

198,582

Total current assets

Ìý

Ìý

2,448,058

Ìý

Ìý

2,492,441

Ìý

Ìý

Ìý

Ìý

Ìý

Property, plant and equipment, net

Ìý

Ìý

1,260,909

Ìý

Ìý

1,271,134

Operating lease right-of-use assets, net

Ìý

Ìý

116,674

Ìý

Ìý

113,376

Goodwill

Ìý

Ìý

491,072

Ìý

Ìý

442,630

Intangible assets, net

Ìý

Ìý

103,485

Ìý

Ìý

103,488

Deferred tax assets

Ìý

Ìý

1,548,229

Ìý

Ìý

1,557,372

Other assets

Ìý

Ìý

250,667

Ìý

Ìý

234,159

Ìý

Ìý

Ìý

Ìý

Ìý

Total assets

Ìý

$

6,219,094

Ìý

$

6,214,600

Ìý

Ìý

Ìý

Ìý

Ìý

LIABILITIES AND STOCKHOLDERS� EQUITY

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Current liabilities:

Ìý

Ìý

Ìý

Ìý

Accounts payable

Ìý

$

114,434

Ìý

$

108,693

Accrued liabilities

Ìý

Ìý

563,059

Ìý

Ìý

598,188

Deferred revenues

Ìý

Ìý

1,317,990

Ìý

Ìý

1,331,146

Total current liabilities

Ìý

Ìý

1,995,483

Ìý

Ìý

2,038,027

Ìý

Ìý

Ìý

Ìý

Ìý

Income tax payable

Ìý

Ìý

103,558

Ìý

Ìý

96,466

Operating lease liabilities

Ìý

Ìý

90,474

Ìý

Ìý

88,214

Other long-term liabilities

Ìý

Ìý

116,800

Ìý

Ìý

139,908

Total liabilities

Ìý

Ìý

2,306,315

Ìý

Ìý

2,362,615

Ìý

Ìý

Ìý

Ìý

Ìý

Total stockholders� equity

Ìý

Ìý

3,912,779

Ìý

Ìý

3,851,985

Ìý

Ìý

Ìý

Ìý

Ìý

Total liabilities and stockholders� equity

Ìý

$

6,219,094

Ìý

$

6,214,600

ALIGN TECHNOLOGY, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)

Ìý

Ìý

Six Months Ended
June 30,

Ìý

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

CASH FLOWS FROM OPERATING ACTIVITIES

Ìý

Ìý

Ìý

Ìý

Net cash provided by operating activities

Ìý

$

181,326

Ìý

Ìý

$

188,491

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

CASH FLOWS FROM INVESTING ACTIVITIES

Ìý

Ìý

Ìý

Ìý

Net cash used in investing activities

Ìý

Ìý

(56,768

)

Ìý

Ìý

(192,077

)

Ìý

Ìý

Ìý

Ìý

Ìý

CASH FLOWS FROM FINANCING ACTIVITIES

Ìý

Ìý

Ìý

Ìý

Net cash used in financing activities

Ìý

Ìý

(303,055

)

Ìý

Ìý

(163,275

)

Ìý

Ìý

Ìý

Ìý

Ìý

Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash

Ìý

Ìý

35,876

Ìý

Ìý

Ìý

(9,196

)

Net decrease in cash, cash equivalents, and restricted cash

Ìý

Ìý

(142,621

)

Ìý

Ìý

(176,057

)

Cash, cash equivalents, and restricted cash at beginning of the period

Ìý

Ìý

1,044,963

Ìý

Ìý

Ìý

938,519

Ìý

Cash, cash equivalents, and restricted cash at end of the period

Ìý

$

902,342

Ìý

Ìý

$

762,462

Ìý

ALIGN TECHNOLOGY, INC.
INVISALIGN BUSINESS METRICS

Ìý

Ìý

Q1

Ìý

Q2

Ìý

Q3

Ìý

Q4

Ìý

Fiscal

Ìý

Q1

Ìý

Q2

Ìý

Ìý

2024

Ìý

2024

Ìý

2024

Ìý

2024

Ìý

2024

Ìý

2025

Ìý

2025

Number of Invisalign Trained Doctors Cases Were Shipped To

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

83,510

Ìý

Ìý

86,135

Ìý

Ìý

87,380

Ìý

Ìý

85,685

Ìý

Ìý

130,370

Ìý

Ìý

85,275

Ìý

Ìý

86,250

Invisalign Trained Doctor Utilization Rates*

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

7.2

Ìý

Ìý

7.5

Ìý

Ìý

7.1

Ìý

Ìý

7.3

Ìý

Ìý

19.1

Ìý

Ìý

7.5

Ìý

Ìý

7.5

Clear Aligner Revenue Per Case Shipment**

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

$

1,350

Ìý

$

1,295

Ìý

$

1,275

Ìý

$

1,265

Ìý

$

1,295

Ìý

$

1,240

Ìý

$

1,250

* number of cases shipped / number of doctors to whom cases were shipped
** Clear Aligner revenues / Case shipments

ALIGN TECHNOLOGY, INC.
STOCK-BASED COMPENSATION
(in thousands)

Ìý

Ìý

Q1

Ìý

Q2

Ìý

Q3

Ìý

Q4

Ìý

Fiscal

Ìý

Q1

Ìý

Q2

Ìý

Ìý

2024

Ìý

2024

Ìý

2024

Ìý

Ìý

2024

Ìý

Ìý

2024

Ìý

2025

Ìý

2025

Stock-based Compensation (SBC):

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

SBC included in Gross Profit

Ìý

$

2,064

Ìý

$

2,582

Ìý

$

3,070

Ìý

$

(721

)

Ìý

$

6,995

Ìý

$

1,538

Ìý

$

1,636

SBC included in Operating Expenses

Ìý

Ìý

36,724

Ìý

Ìý

44,446

Ìý

Ìý

45,969

Ìý

Ìý

39,569

Ìý

Ìý

Ìý

166,708

Ìý

Ìý

43,459

Ìý

Ìý

46,572

Total SBC

Ìý

$

38,788

Ìý

$

47,028

Ìý

$

49,039

Ìý

$

38,848

Ìý

Ìý

$

173,703

Ìý

$

44,997

Ìý

$

48,208

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

ALIGN TECHNOLOGY, INC.
UNAUDITED GAAP TO NON-GAAP RECONCILIATION+
CONSTANT CURRENCY NET REVENUES
(in thousands, except percentages)

Sequential constant currency analysis:

Ìý

Ìý

Three Months Ended

Ìý

Ìý

Ìý

Ìý

June 30,
2025

Ìý

March 31,
2025

Ìý

Impact % of Revenue

GAAP net revenues

Ìý

$

1,012,449

Ìý

Ìý

$

979,262

Ìý

Ìý

Constant currency impact (1)

Ìý

Ìý

(26,388

)

Ìý

Ìý

Ìý

(2.7

)%

Constant currency net revenues (1)

Ìý

$

986,061

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

GAAP Clear Aligner net revenues

Ìý

$

804,617

Ìý

Ìý

$

796,843

Ìý

Ìý

Clear Aligner constant currency impact (1)

Ìý

Ìý

(21,629

)

Ìý

Ìý

Ìý

(2.8

)%

Clear Aligner constant currency net revenues (1)

Ìý

$

782,988

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

GAAP Imaging Systems and CAD/CAM Services net revenues

Ìý

$

207,832

Ìý

Ìý

$

182,419

Ìý

Ìý

Imaging Systems and CAD/CAM Services constant currency impact (1)

Ìý

Ìý

(4,759

)

Ìý

Ìý

Ìý

(2.3

)%

Imaging Systems and CAD/CAM Services constant currency net revenues (1)

Ìý

$

203,073

Ìý

Ìý

Ìý

Ìý

Ìý

Year-over-year constant currency analysis:

Ìý

Ìý

Three Months Ended

June 30,

Ìý

Ìý

Ìý

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

Impact % of Revenue

GAAP net revenues

Ìý

$

1,012,449

Ìý

Ìý

$

1,028,490

Ìý

Ìý

Constant currency impact (1)

Ìý

Ìý

(5,553

)

Ìý

Ìý

Ìý

(0.6

)%

Constant currency net revenues (1)

Ìý

$

1,006,896

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

GAAP Clear Aligner net revenues

Ìý

$

804,617

Ìý

Ìý

$

831,738

Ìý

Ìý

Clear Aligner constant currency impact (1)

Ìý

Ìý

(4,545

)

Ìý

Ìý

Ìý

(0.6

)%

Clear Aligner constant currency net revenues (1)

Ìý

$

800,072

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

GAAP Imaging Systems and CAD/CAM Services net revenues

Ìý

$

207,832

Ìý

Ìý

$

196,752

Ìý

Ìý

Imaging Systems and CAD/CAM Services constant currency impact (1)

Ìý

Ìý

(1,008

)

Ìý

Ìý

Ìý

(0.5

)%

Imaging Systems and CAD/CAM Services constant currency net revenues (1)

Ìý

$

206,824

Ìý

Ìý

Ìý

Ìý

Ìý

Note:
(1) We define constant currency net revenues as total net revenues excluding the effect of foreign exchange rate movements and use it to determine the percentage for the constant currency impact on net revenues on a sequential and year-over-year basis. Constant currency impact in dollars is calculated by translating the current period GAAP net revenues using the foreign currency exchange rates that were in effect during the previous comparable period and subtracting it by the current period GAAP net revenues. The percentage for the constant currency impact on net revenues is calculated by dividing the constant currency impact in dollars (numerator) by constant currency net revenues in dollars (denominator).
(+) Changes and percentages are based on actual values. Certain tables may not sum or recalculate due to rounding. Refer to "About Non-GAAP Financial Measures" section of press release.

ALIGN TECHNOLOGY, INC.
UNAUDITED GAAP TO NON-GAAP RECONCILIATION CONTINUED+
CONSTANT CURRENCY GROSS PROFIT AND GROSS MARGIN
(in thousands, except percentages)

Sequential constant currency analysis:

Ìý

Ìý

Three Months Ended

Ìý

Ìý

June 30,
2025

Ìý

March 31,
2025

GAAP gross profit

Ìý

$

708,117

Ìý

Ìý

$

680,108

Constant currency impact on net revenues

Ìý

Ìý

(26,388

)

Ìý

Ìý

Constant currency gross profit

Ìý

$

681,728

Ìý

Ìý

Ìý

Ìý

Ìý

Three Months Ended

Ìý

Ìý

June 30,
2025

Ìý

March 31,
2025

GAAP gross margin

Ìý

69.9

%

Ìý

69.5

%

Gross margin constant currency impact (1)

Ìý

(0.8

)

Ìý

Ìý

Constant currency gross margin (1)

Ìý

69.1

%

Ìý

Ìý

Year-over-year constant currency analysis:

Ìý

Ìý

Three Months Ended

June 30,

Ìý

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

GAAP gross profit

Ìý

$

708,117

Ìý

Ìý

$

722,628

Constant currency impact on net revenues

Ìý

Ìý

(5,553

)

Ìý

Ìý

Constant currency gross profit

Ìý

$

702,564

Ìý

Ìý

Ìý

Ìý

Ìý

Three Months Ended

June 30,

Ìý

Ìý

2025

Ìý

Ìý

2024

Ìý

GAAP gross margin

Ìý

69.9

%

Ìý

70.3

%

Gross margin constant currency impact (1)

Ìý

(0.2

)

Ìý

Ìý

Constant currency gross margin (1)

Ìý

69.8

%

Ìý

Ìý

Ìý

Note:
(1) We define constant currency gross margin as constant currency gross profit as a percentage of constant currency net revenues. Gross margin constant currency impact is the increase or decrease in constant currency gross margin compared to the GAAP gross margin.
(+) Changes and percentages are based on actual values. Certain tables may not sum or recalculate due to rounding. Refer to "About Non-GAAP Financial Measures" section of press release.

ALIGN TECHNOLOGY, INC.
UNAUDITED GAAP TO NON-GAAP RECONCILIATION CONTINUED+
CONSTANT CURRENCY INCOME FROM OPERATIONS AND OPERATING MARGIN
(in thousands, except percentages)

Sequential constant currency analysis:

Ìý

Ìý

Three Months Ended

Ìý

Ìý

June 30,
2025

Ìý

March 31,
2025

GAAP income from operations

Ìý

$

163,033

Ìý

Ìý

$

131,100

Income from operations constant currency impact (1)

Ìý

Ìý

(16,128

)

Ìý

Ìý

Constant currency income from operations (1)

Ìý

$

146,905

Ìý

Ìý

Ìý

Ìý

Ìý

Three Months Ended

Ìý

Ìý

June 30,
2025

Ìý

March 31,
2025

GAAP operating margin

Ìý

16.1

%

Ìý

13.4

%

Operating margin constant currency impact (2)

Ìý

(1.2

)

Ìý

Ìý

Constant currency operating margin (2)

Ìý

14.9

%

Ìý

Ìý

Year-over-year constant currency analysis:

Ìý

Ìý

Three Months Ended

June 30,

Ìý

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

GAAP income from operations

Ìý

$

163,033

Ìý

Ìý

$

147,046

Income from operations constant currency impact (1)

Ìý

Ìý

(3,232

)

Ìý

Ìý

Constant currency income from operations (1)

Ìý

$

159,801

Ìý

Ìý

Ìý

Ìý

Ìý

Three Months Ended

June 30,

Ìý

Ìý

2025

Ìý

Ìý

2024

Ìý

GAAP operating margin

Ìý

16.1

%

Ìý

14.3

%

Operating margin constant currency impact (2)

Ìý

(0.2

)

Ìý

Ìý

Constant currency operating margin (2)

Ìý

15.9

%

Ìý

Ìý

Ìý

Notes:
(1) We define constant currency income from operations as GAAP income from operations excluding the effect of foreign exchange rate movements for GAAP net revenues and operating expenses on a sequential and year-over-year basis. Constant currency impact in dollars is calculated by translating the current period GAAP net revenues and operating expenses using the foreign currency exchange rates that were in effect during the previous comparable period and subtracting it by the current period GAAP net revenues and operating expenses.
(2) We define constant currency operating margin as constant currency income from operations as a percentage of constant currency net revenues. Operating margin constant currency impact is the increase or decrease in constant currency operating margin compared to the GAAP operating margin.
(+) Changes and percentages are based on actual values. Certain tables may not sum or recalculate due to rounding. Refer to "About Non-GAAP Financial Measures" section of press release.

ALIGN TECHNOLOGY, INC.
UNAUDITED GAAP TO NON-GAAP RECONCILIATION CONTINUED+
FINANCIAL MEASURES OTHER THAN CONSTANT CURRENCY
(in thousands, except per share data)

Ìý

Ìý

Three Months Ended

June 30,

Ìý

Six Months Ended

June 30,

Ìý

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

GAAP gross profit

Ìý

$

708,117

Ìý

Ìý

$

722,628

Ìý

Ìý

$

1,388,225

Ìý

Ìý

$

1,420,444

Ìý

Stock-based compensation

Ìý

Ìý

1,636

Ìý

Ìý

Ìý

2,582

Ìý

Ìý

Ìý

3,174

Ìý

Ìý

Ìý

4,646

Ìý

Amortization of intangibles (1)

Ìý

Ìý

3,752

Ìý

Ìý

Ìý

3,678

Ìý

Ìý

Ìý

7,301

Ìý

Ìý

Ìý

7,402

Ìý

Restructuring charges (2)

Ìý

Ìý

�

Ìý

Ìý

Ìý

�

Ìý

Ìý

Ìý

2,253

Ìý

Ìý

Ìý

�

Ìý

Non-GAAP gross profit

Ìý

$

713,505

Ìý

Ìý

$

728,888

Ìý

Ìý

$

1,400,953

Ìý

Ìý

$

1,432,492

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

GAAP gross margin

Ìý

Ìý

69.9

%

Ìý

Ìý

70.3

%

Ìý

Ìý

69.7

%

Ìý

Ìý

70.1

%

Non-GAAP gross margin

Ìý

Ìý

70.5

%

Ìý

Ìý

70.9

%

Ìý

Ìý

70.3

%

Ìý

Ìý

70.7

%

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

GAAP total operating expenses

Ìý

$

545,084

Ìý

Ìý

$

575,582

Ìý

Ìý

$

1,094,092

Ìý

Ìý

$

1,119,263

Ìý

Stock-based compensation

Ìý

Ìý

(46,572

)

Ìý

Ìý

(44,446

)

Ìý

Ìý

(90,031

)

Ìý

Ìý

(81,170

)

Amortization of intangibles (1)

Ìý

Ìý

(904

)

Ìý

Ìý

(875

)

Ìý

Ìý

(1,745

)

Ìý

Ìý

(1,738

)

Restructuring and other charges (2)

Ìý

Ìý

�

Ìý

Ìý

Ìý

357

Ìý

Ìý

Ìý

197

Ìý

Ìý

Ìý

357

Ìý

Legal settlement loss

Ìý

Ìý

�

Ìý

Ìý

Ìý

(31,127

)

Ìý

Ìý

(4,178

)

Ìý

Ìý

(31,127

)

Non-GAAP total operating expenses

Ìý

$

497,608

Ìý

Ìý

$

499,491

Ìý

Ìý

$

998,335

Ìý

Ìý

$

1,005,585

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

GAAP income from operations

Ìý

$

163,033

Ìý

Ìý

$

147,046

Ìý

Ìý

$

294,133

Ìý

Ìý

$

301,181

Ìý

Stock-based compensation

Ìý

Ìý

48,208

Ìý

Ìý

Ìý

47,028

Ìý

Ìý

Ìý

93,205

Ìý

Ìý

Ìý

85,816

Ìý

Amortization of intangibles (1)

Ìý

Ìý

4,656

Ìý

Ìý

Ìý

4,553

Ìý

Ìý

Ìý

9,046

Ìý

Ìý

Ìý

9,140

Ìý

Restructuring and other charges (2)

Ìý

Ìý

�

Ìý

Ìý

Ìý

(357

)

Ìý

Ìý

2,056

Ìý

Ìý

Ìý

(357

)

Legal settlement loss

Ìý

Ìý

�

Ìý

Ìý

Ìý

31,127

Ìý

Ìý

Ìý

4,178

Ìý

Ìý

Ìý

31,127

Ìý

Non-GAAP income from operations

Ìý

$

215,897

Ìý

Ìý

$

229,397

Ìý

Ìý

$

402,618

Ìý

Ìý

$

426,907

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

GAAP operating margin

Ìý

Ìý

16.1

%

Ìý

Ìý

14.3

%

Ìý

Ìý

14.8

%

Ìý

Ìý

14.9

%

Non-GAAP operating margin

Ìý

Ìý

21.3

%

Ìý

Ìý

22.3

%

Ìý

Ìý

20.2

%

Ìý

Ìý

21.1

%

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

GAAP net income before provision for income taxes

Ìý

$

173,516

Ìý

Ìý

$

143,866

Ìý

Ìý

$

313,958

Ìý

Ìý

$

302,252

Ìý

Stock-based compensation

Ìý

Ìý

48,208

Ìý

Ìý

Ìý

47,028

Ìý

Ìý

Ìý

93,205

Ìý

Ìý

Ìý

85,816

Ìý

Amortization of intangibles (1)

Ìý

Ìý

4,656

Ìý

Ìý

Ìý

4,553

Ìý

Ìý

Ìý

9,046

Ìý

Ìý

Ìý

9,140

Ìý

Restructuring and other charges (2)

Ìý

Ìý

�

Ìý

Ìý

Ìý

(357

)

Ìý

Ìý

2,056

Ìý

Ìý

Ìý

(357

)

Legal settlement loss

Ìý

Ìý

�

Ìý

Ìý

Ìý

31,127

Ìý

Ìý

Ìý

4,178

Ìý

Ìý

Ìý

31,127

Ìý

Non-GAAP net income before provision for income taxes

Ìý

$

226,380

Ìý

Ìý

$

226,217

Ìý

Ìý

$

422,443

Ìý

Ìý

$

427,978

Ìý

ALIGN TECHNOLOGY, INC.
UNAUDITED GAAP TO NON-GAAP RECONCILIATION CONTINUED
FINANCIAL MEASURES OTHER THAN CONSTANT CURRENCY CONTINUED
(in thousands, except per share data)

Ìý

Ìý

Three Months Ended

June 30,

Ìý

Six Months Ended

June 30,

Ìý

Ìý

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

Ìý

GAAP provision for income taxes

Ìý

$

48,908

Ìý

Ìý

$

47,302

Ìý

Ìý

$

96,120

Ìý

Ìý

$

100,660

Ìý

Ìý

Tax impact on non-GAAP adjustments

Ìý

Ìý

(3,631

)

Ìý

Ìý

(2,059

)

Ìý

Ìý

(11,631

)

Ìý

Ìý

(15,095

)

Ìý

Non-GAAP provision for income taxes

Ìý

$

45,277

Ìý

Ìý

$

45,243

Ìý

Ìý

$

84,489

Ìý

Ìý

$

85,565

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

GAAP effective tax rate

Ìý

Ìý

28.2

%

Ìý

Ìý

32.9

%

Ìý

Ìý

30.6

%

Ìý

Ìý

33.3

%

Ìý

Non-GAAP effective tax rate

Ìý

Ìý

20.0

%

Ìý

Ìý

20.0

%

Ìý

Ìý

20.0

%

Ìý

Ìý

20.0

%

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

GAAP net income

Ìý

$

124,608

Ìý

Ìý

$

96,564

Ìý

Ìý

$

217,838

Ìý

Ìý

$

201,592

Ìý

Ìý

Stock-based compensation

Ìý

Ìý

48,208

Ìý

Ìý

Ìý

47,028

Ìý

Ìý

Ìý

93,205

Ìý

Ìý

Ìý

85,816

Ìý

Ìý

Amortization of intangibles (1)

Ìý

Ìý

4,656

Ìý

Ìý

Ìý

4,553

Ìý

Ìý

Ìý

9,046

Ìý

Ìý

Ìý

9,140

Ìý

Ìý

Restructuring and other charges (2)

Ìý

Ìý

�

Ìý

Ìý

Ìý

(357

)

Ìý

Ìý

2,056

Ìý

Ìý

Ìý

(357

)

Ìý

Legal settlement loss

Ìý

Ìý

�

Ìý

Ìý

Ìý

31,127

Ìý

Ìý

Ìý

4,178

Ìý

Ìý

Ìý

31,127

Ìý

Ìý

Tax impact on non-GAAP adjustments

Ìý

Ìý

3,631

Ìý

Ìý

Ìý

2,059

Ìý

Ìý

Ìý

11,631

Ìý

Ìý

Ìý

15,095

Ìý

Ìý

Non-GAAP net income

Ìý

$

181,103

Ìý

Ìý

$

180,974

Ìý

Ìý

$

337,954

Ìý

Ìý

$

342,413

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

GAAP diluted net income per share

Ìý

$

1.72

Ìý

Ìý

$

1.28

Ìý

Ìý

$

2.98

Ìý

Ìý

$

2.68

Ìý

Ìý

Non-GAAP diluted net income per share

Ìý

$

2.49

Ìý

Ìý

$

2.41

Ìý

Ìý

$

4.62

Ìý

Ìý

$

4.55

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Shares used in computing diluted net income per share

Ìý

Ìý

72,593

Ìý

Ìý

Ìý

75,223

Ìý

Ìý

Ìý

73,098

Ìý

Ìý

Ìý

75,315

Ìý

Ìý

Ìý

Notes:
(1) Amortization of intangible assets related to certain acquisitions.
(2) During the fourth quarter 2024, we initiated restructuring plans to reduce headcount and increase efficiencies across the organization and lower the overall cost structure. Restructuring charges are primarily related to severance and other post-employment one-time benefits.
(+) Changes and percentages are based on actual values. Certain tables may not sum or recalculate due to rounding. Refer to "About Non-GAAP Financial Measures" section of press release.

ALIGN TECHNOLOGY, INC.

Q3 2025 OUTLOOK - GAAP TO NON-GAAP RECONCILIATION

GAAP gross margin

Ìý

64.0% - 65.0%

Stock-based compensation

Ìý

~0.1%

Amortization of intangibles (1)

Ìý

~0.5%

Asset write-down and Restructuring charges (2)

Ìý

~5.0% - 6.0%

Non-GAAP gross margin

Ìý

Approximately 70.5%

GAAP operating margin

Ìý

10.5% - 11.5%

Stock-based compensation

Ìý

~5.0%

Amortization of intangibles (1)

Ìý

~0.5%

Asset write-down and Restructuring charges (2)

Ìý

~5.0% - 6.0%

Non-GAAP operating margin

Ìý

Approximately 22.0%

ALIGN TECHNOLOGY, INC.

FISCAL 2025 OUTLOOK - GAAP TO NON-GAAP RECONCILIATION

GAAP gross margin

Ìý

67.0% - 68.0%

Stock-based compensation

Ìý

~0.1%

Amortization of intangibles (1)

Ìý

~0.5%

Asset write-down and Restructuring charges (2)

Ìý

~2.0% - 3.0%

Non-GAAP gross margin

Ìý

Approximately 70.5%

Percentages do not add up due to rounding.

GAAP operating margin

Ìý

13.0% - 14.0%

Stock-based compensation

Ìý

~4.5%

Amortization of intangibles (1)

Ìý

~0.5%

Asset write-down and Restructuring charges (2)

Ìý

~3.5% - 4.5%

Legal settlement loss (3)

Ìý

~0.1%

Non-GAAP operating margin

Ìý

Approximately 22.5%

Percentages do not add up due to rounding.

(1) Amortization of intangible assets related to certain acquisitions
(2) Asset write-down, accelerated depreciation and restructuring charges
(3) Legal settlement loss from Q1'25

Refer to "About Non-GAAP Financial Measures" section of press release.

Align Technology

Madelyn Valente

(909) 833-5839

[email protected]

Zeno Group

Sarah Karlson

(828) 551-4201

[email protected]

Source: Align Technology, Inc.

Align Technology Inc

NASDAQ:ALGN

ALGN Rankings

ALGN Latest News

ALGN Latest SEC Filings

ALGN Stock Data

15.02B
67.65M
6.67%
91.19%
5.13%
Medical Instruments & Supplies
Orthopedic, Prosthetic & Surgical Appliances & Supplies
United States
TEMPE